Ligand Pharmaceuticals Incorporated (LGND) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 17 analysts3.5% Above Target
LGND trades 3.5% above Wall Street's consensus target of $265.33.
Current Price$274.88
Average Target$265.33
Target
Current
Low$252.00
Median$255.00
High$289.00
Analyst Target Range
Forward P/E30.3x
(Growth Premium)
PEG Ratio—
Implied Growth+17.3%
(Moderate)
Analyst Spread13.9%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes LGND achieves its forward estimates and maintains a stable P/E multiple of 30.3x. This scenario reflects the blended consensus of 17 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
LGND Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Ligand Pharmaceuticals Incorporated (LGND) has a Wall Street consensus price target of $265.33, based on estimates from 17 covering analysts. With the stock currently trading at $274.88, this represents a potential downside of -3.5%. The company has a market capitalization of $5.51B.
Analyst price targets range from a low of $252.00 to a high of $289.00, representing a 14% spread in expectations. The median target of $255.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 12 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LGND trades at a trailing P/E of 44.8x and forward P/E of 30.3x. Analysts expect EPS to grow +17.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $223.30, with bear and bull scenarios of $140.68 and $294.23 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+56.9%
Industry Consensus
Avg Forward P/E
14.2x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRGOPerrigo Company plc | $1.4B | $10.25 | $36.20 | +253.2% | Hold | 4.8x | 36 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 OMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V. | $5.5B | $114.00 | $127.00 | +11.4% | Buy | 0.8x | 13 |
 RPRXRoyalty Pharma plc | $22.7B | $52.96 | $56.67 | +7.0% | Buy | 10.3x | 11 |
 BCYCBicycle Therapeutics plc | $277M | $4.00 | $10.67 | +166.8% | Buy | — | 21 |
 XOMAXOMA Royalty Corp. | $525M | $41.89 | $44.50 | +6.2% | Buy | 53.3x | 10 |
 NUVLNuvalent, Inc. | $9.1B | $123.43 | $132.74 | +7.5% | Hold | — | 18 |
 RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
 ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
 PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
LGND — Frequently Asked Questions
Quick answers to the most common questions about buying LGND stock.
What is the LGND stock price target for 2026?
Wall Street's consensus price target for LGND is $265.33, -3.5% from its current price of $274.88. The below-market target from 17 analysts suggests limited near-term appreciation.
Is LGND a buy, sell, or hold?
LGND has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 12 Buy/Strong Buy ratings. The consensus 12-month price target of $265.33 implies -3.5% downside from current levels.
Is LGND stock overvalued or undervalued?
LGND trades at a forward P/E of 30.3483x, representing a moderate valuation. With analysts targeting $265.33 (-3.5% implied move), the stock appears close to fair value.
How high can LGND stock go?
The most bullish Wall Street analyst has a price target of $289 for LGND, while the most conservative target is $252. The consensus of $265.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $294 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover LGND stock?
LGND is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LGND stock forecast?
The 12-month LGND stock forecast based on 17 Wall Street analysts shows a consensus price target of $265.33, with estimates ranging from $252 (bear case) to $289 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $223, with bear/bull scenarios of $141/$294.
What is LGND's fair value based on fundamentals?
Our quantitative valuation model calculates LGND's fair value at $223 (base case), with a bear case of $141 and bull case of $294. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
What is LGND's forward P/E ratio?
LGND trades at a forward P/E ratio of 30.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 44.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy LGND stock?
Analysts are cautious on LGND, with 1 Sell ratings and a price target of $265.33 (-3.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LGND price targets vary so much?
LGND analyst price targets range from $252 to $289, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $265.33 consensus represents the middle ground. Our model's $141-$294 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare